MaxCyte, Inc. Introduces Rapid, Automated, Scalable Flow Electroporation-Based Technology For Vaccine Development
3/20/2014 10:11:22 AM
GAITHERSBURG, Md.--(BUSINESS WIRE)--MaxCyte®, Inc., the pioneer in scalable, high-performance cell transfection systems, will present data in both a scientific talk and a poster during the World Vaccine Congress on March 24-26, 2014, that demonstrates the use of flow electroporation for the rapid and scalable transfection of cells in vaccine development. The data will show that MaxCyte’s technology enables the manufacture of multiple-gram quantities of recombinant protein antigens, virus-like particles (VLPs), viral vectors, or viruses for tens of thousands of doses in a single process run.
Help employers find you! Check out all the jobs and post your resume.
comments powered by